Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Global Market Opportunities And Strategies To 2035

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Definition

Chimeric antigen receptor-natural killer (CAR-NK) cell therapy is an advanced form of cellular immunotherapy that utilizes natural killer (NK) cells engineered or expanded to recognize and destroy cancer cells through the expression of chimeric antigen receptors (CARs). CAR-NK therapy combines the innate cytotoxic capabilities of NK cells with the tumor-targeting specificity conferred by genetic modification, enabling targeted immune responses against malignant cells. The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market consists of sales by entities (organizations, sole traders and partnerships) of CAR-NK cell therapy used in the treatment of various cancers, particularly hematological malignancies and solid tumors, and is administered to patients who may have relapsed, refractory, or treatment-resistant disease. The therapy is typically used when conventional treatments such as chemotherapy, radiation therapy, surgery, or hematopoietic stem cell transplantation are ineffective or unsuitable. CAR-NK cell therapy may also be explored earlier in treatment or in combination with other immunotherapies to enhance therapeutic outcomes.

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Segmentation

The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market is segmented by type, by cell source, by application, and by end user.

By Type –
The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market is segmented by type into:

• a) Adoptive Natural Killer (NK) Cell Therapy
• b) Genetically Engineered Natural Killer Cell Therapy
• c) Other Types

The genetically engineered natural killer cell therapy segment is expected to be the fastest-growing segment in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by type, at a CAGR of 42.3% during 2030-2035.

By Cell Source –
The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market is segmented by cell source into:

• a) Peripheral Blood-Derived Natural Killer Cells
• b) Cord Blood-Derived Natural Killer Cells
• c) Induced Pluripotent Stem Cell (Ipsc)-Derived Natural Killer Cells
• d) Natural Killer Cell Lines

The induced pluripotent stem cell derived natural killer cells segment is expected to be the fastest-growing segment in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by cell source, at a CAGR of 51.9% during 2030-2035.

By Application –
The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market is segmented by application into:

• a) Solid Tumors
• b) Hematological Malignancies
• c) Other Applications

The solid tumors segment is expected to be the fastest-growing segment in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by application, at a CAGR of 42.6% during 2030-2035.

By End User –
The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market is segmented by end user into:

• a) Hospitals
• b) Cancer Research Institutes
• c) Biotechnology And Pharmaceutical Companies

The hospitals segment is expected to be the fastest-growing segment in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by end user, at a CAGR of 39.3% during 2025-2030.

By Geography - The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market is segmented by geography into:

o Asia Pacific
• China
• India
• Japan
• Australia
• Indonesia
• South Korea
o North America
• USA
• Canada
o South America
• Brazil
o Western Europe
• France
• Germany
• UK
• Italy
• Spain
o Eastern Europe
• Russia
o Middle East
o Africa

North America is expected to be the largest region in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market, accounting $743.0 million of the total in 2030. It was followed by Western Europe, Asia Pacific and then the other regions. Going forward, the fastest-growing regions in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market will be Middle East and Asia Pacific where growth will be at CAGRs of 59.2% and 49.7% respectively. These will be followed by Western Europe and North America where the markets are expected to grow at CAGRs of 38.0% and 30.3% respectively.

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Competitive Landscape

Major Competitors are:

ImmunityBio Inc.

PersonGen Biomedicine

Fate Therapeutics Inc.

Nkarta Therapeutics Inc.

Senti Biosciences, Inc.

Other Competitors Include:

Artiva Biotherapeutics

Century Therapeutics

Catamaran Bio

Wugen Therapeutics Inc.

Acepodia

Glycostem Therapeutics Ltd.

GICELL Co. Ltd

Nuwacell Biotechnologies Co. Ltd.

NKGen Biotech Inc.

HekaBio K.K.

GC Cell Corporation

Cell Therapies Pty Ltd

ENCell Co., Ltd

Miltenyi Biotec Korea Co., Ltd.

CHA Biotech

Daewoong group

Hangzhou Rongze Biotechnology Group Co., Ltd

PersonGen BioTherapeutics (Suzhou) Co. Ltd

Allife Medical Science and Technology Co., Ltd.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

ONO Pharmaceutical Co., Ltd.

Kirin Holdings Company, Limited

Fate Therapeutics

Beijing Gene MiNK Biotechnology Co., Ltd

Immuneel Therapeutics Private Limited

East Ocyon Bio

NKure Therapeutics

Eyestem

Aurigene Oncology

CiRA Foundation

CytoMed Therapeutics (GDTC)

Cordlife Group Limited Genepeutic Bio Co., Ltd.

SCG Cell Therapy Pte Ltd

NK BioCell

Auxi Therapeutics Sdn Bhd

Cordlife Vietnam

Ophelos Therapeutics

Alloy Therapeutics

OmniaBio Inc.

Ankarys Therapeutics Inc.

BioCanRx

Kiadis Pharma

Affimed N.V.

Innate Pharma SA

Kuur Therapeutics

T&L Biotechnology

Celluris

SOTIO Biotech

SCTbio

Niba Labs

NatiVita

Enzym Group

Celularity, Inc.

Takeda Pharma

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Drivers

The key drivers of the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market include: Increase In Government Funding For Cancer Research During the forecast period, the increase in government funding for cancer research is expected to be a key driver propelling growth in the CAR-NK cell therapy market. As governments allocate higher budgets to oncology research in response to the rising global cancer burden and the need for more effective and safer treatment options, public institutions and research centers expand laboratory capabilities, translational research programs, and early-stage clinical investigations focused on advanced immunotherapies. A stronger public funding base increases the number of investigator-initiated studies, supports multicenter clinical trials, and accelerates technology transfer from academic laboratories to biotechnology companies, which drives sustained demand for CAR-NK cell engineering platforms, viral and non-viral vector systems, and scalable cell manufacturing solutions. As a result, CAR-NK therapy developers are strengthening research collaborations, expanding clinical trial pipelines, and investing in GMP-compliant manufacturing infrastructure to align with national funding priorities and sustain long-term growth in the global CAR-NK cell therapy market.

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Restraints

The key restraints on the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market include: During the forecast period, high hospitalization and monitoring costs are expected to restrain the growth of the Chimeric Antigen Receptor-Natural Killer (CAR-NK) cell therapy market. Persistent expenses associated with inpatient hospital stays, specialized oncology ward infrastructure, intensive patient monitoring, management of immune-related adverse events, and post-infusion follow-up care are placing significant financial pressure on healthcare providers, payers, and patients, which in turn discourages broader adoption beyond specialized treatment centers. From a clinical and operational perspective, the need for advanced diagnostic testing, biomarker assessments, continuous vital monitoring, and multidisciplinary medical supervision increases the overall cost burden of CAR-NK therapy administration, compelling hospitals and cancer centers to carefully evaluate reimbursement pathways and budget allocations before expanding treatment capacity. These hospitalization and monitoring cost dynamics, coupled with limited reimbursement clarity, high insurance approval thresholds, and disparities in healthcare funding across regions, intensify financial constraints and heighten the risk of restricted patient access and delayed therapy uptake. As a result, biotechnology developers, treatment providers, and healthcare systems may face slower commercial scaling, cautious expansion into community oncology settings, and postponed investments in broader CAR-NK clinical program deployment during the forecast period.

Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market Trends

Major trends shaping the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market include: Biotechnology, Genomics & Precision Medicine Major companies in the CAR-NK cell therapy market are increasingly prioritizing precision genetic engineering, including iPSC-derived NK platforms and multi-target CAR constructs, to enable standardized, off-the-shelf products while reducing dependence on donor variability and antigen escape. This is shaping the market by improving product consistency and scalability, strengthening clinical translation of next-generation CAR-NK designs across hematologic cancers and investigational expansion areas. For example, in 2026, Century Therapeutics, a US-based biotechnology company, highlights in its pipeline that CNTY-101 is an iPSC-derived CAR-iNK (CAR-NK) cell therapy engineered with six precision gene edits and positioned for B-cell–mediated autoimmune diseases, illustrating how biotechnology, genomics, and precision medicine are reshaping CAR-NK development around precision-edited, off-the-shelf cell platforms. Digitalization, Cloud, Big Data & Cybersecurity Major companies in the CAR-NK cell therapy market are increasingly prioritizing digitally governed engineering and quality-control workflows, including sequenced master cell lines, data-driven clone selection, and structured management of genomic manufacturing datasets, to improve reproducibility and regulatory readiness while reducing reliance on low-visibility biological variability. This is strengthening large-scale CAR-NK translation by enabling audit-ready off-the-shelf products supported by secure genomic data packages and standardized release criteria. For example, in May 2025, Qihan Biotech, a China-based cell therapy company, reported in Cell the clinical translation of its dual-targeting iPSC-derived CAR-NK therapy (QN-139b) manufactured from sequenced monoclonal iPSC master cell lines using a high-throughput gene-editing platform, enabling digitally traceable clone selection and standardized quality control, illustrating how digitalization and big-data–driven genomic governance are reshaping CAR-NK development toward reproducible, regulator-ready productization.

Opportunities And Recommendations In The Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapy Market

Opportunities – The top opportunities in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by type will arise in the adoptive natural killer (NK) cell therapy segment, which will gain $457.3 million of global annual sales by 2030. The top opportunities in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by cell source will arise in the peripheral blood-derived natural killer cells segment, which will gain $309.0 million of global annual sales by 2030. The top opportunities in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by application will arise in the hematological malignancies segment, which will gain $567.9 million of global annual sales by 2030. The top opportunities in the chimeric antigen receptor-natural killer (CAR-NK) cell therapy market segmented by end user will arise in the hospitals segment, which will gain $438.4 million of global annual sales by 2030. The chimeric antigen receptor-natural killer (CAR-NK) cell therapy market size will gain the most in the USA at $712.2 million. Recommendations- To take advantage of the opportunities, The Business Research Company recommends the chimeric antigen receptor-natural killer (CAR-NK) cell therapy companies to focus on iPSC-Derived Off-the-Shelf CAR- NK platforms for scalable development, focus on chemotherapy-free regimen innovation to expand clinical accessibility, focus on closed-system GMP manufacturing for scalable CAR-NK production, focus on integrated GMP partnerships to accelerate IND timelines, focus on genetically engineered NK cell therapy for high-growth expansion, focus on iPSC-derived NK cells for scalable commercial growth, expand in emerging markets, specialized centers, focus on value-based and tiered pricing to drive market access, focus on clinical evidence-led promotion to build trust and adoption, focus on stakeholder-centric outreach to expand market awareness, focus on solid tumor applications to capture high-growth demand and focus on hospital channel to drive high-growth adoption.